Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs - Presented by: The Aol. On Network

Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4 percent from the same quarter last year. The sales decline is a result of the company selling its stake in a diabetes alliance with AstraZeneca.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 17.62 0.09 ▲ 0.51%
GE $ 25.62 0.48 ▲ 1.91%
AAPL $ 111.78 0.87 ▼ 0.77%
INTC $ 36.37 0.65 ▼ 1.76%
MSFT $ 47.66 0.14 ▲ 0.29%
IAG $ 2.59 0.01 ▼ 0.38%
PBR/A $ 7.34 0.17 ▲ 2.37%
VALE $ 8.14 0.53 ▲ 6.96%

As of 12/19/2014, 04:15 PM
More Most Active

Latest News Headlines

View All